Prostatype Genomics AB (FRA:PGO) Debt-to-Equity : 0.02 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Prostatype Genomics AB Debt-to-Equity?

Prostatype Genomics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.03 Mil. Prostatype Genomics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.02 Mil. Prostatype Genomics AB's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €2.48 Mil. Prostatype Genomics AB's debt to equity for the quarter that ended in Jun. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Prostatype Genomics AB's Debt-to-Equity or its related term are showing as below:

FRA:PGO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.47 Max: 1.54
Current: 0.47

During the past 5 years, the highest Debt-to-Equity Ratio of Prostatype Genomics AB was 1.54. The lowest was 0.03. And the median was 0.47.

FRA:PGO's Debt-to-Equity is ranked worse than
67.01% of 194 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs FRA:PGO: 0.47

Prostatype Genomics AB Debt-to-Equity Historical Data

The historical data trend for Prostatype Genomics AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Debt-to-Equity Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Debt-to-Equity

1.54

0.80

0.04

0.03

0.47

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											0.03	0.03	0.04	0.02	0.47

Competitive Comparison of Prostatype Genomics AB's Debt-to-Equity

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prostatype Genomics AB's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Debt-to-Equity falls into.

Prostatype Genomics AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Prostatype Genomics AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.037	+	0.006)	/	2.206
	=	0.47

Prostatype Genomics AB's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.034	+	0.023)	/	2.48
	=	0.02

Prostatype Genomics AB (FRA:PGO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Prostatype Genomics AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (FRA:PGO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (FRA:PGO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PROGEN:Sweden

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (FRA:PGO) Headlines

No Headlines